[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atrophic-vaginitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atrophic-vaginitis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100512487","valor-vaginal-atrophy--long-term-observation-of-recovery-100512487",false,"NCT05953090","VALOR: Vaginal Atrophy & Long-term Observation of Recovery","VALOR","Inclusion Criteria:\n\n* Diagnosed atrophic vaginitis, lichen sclerosus, lichen simplex chronicus or lichen planus\n* Continuous vulvovaginal symptoms\n* Access to smartphone and tablet, laptop or computer\n* Access to a valid email address\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Patient unable to apply topical device\n* Allergy or intolerance to ingredients or excipients of the formulation of studied products\n* Systemic hormonal therapy started less than 30 days before baseline\n* Systemic corticosteroids ongoing treatment or used within the last 30 days before baseline\n* Ongoing topical HRT or corticosteroid treatment for the indication under investigation\n* Topical HRT or corticosteroid treatment used for the indication under investigation within the last 30 days before baseline","FEMALE","18 Years",{"count":19,"type":20},2000,"ESTIMATED","INTERVENTIONAL",[23],"NA","Vulvovaginal skin conditions, namely vaginal atrophy, lichen sclerosus, lichen simplex chronicus and lichen planus affecting the female adult population will be treated with a novel gel dressing to test the short- and long-term safety and efficacy of the device.",[26,27,28,29,30,31],"Atrophic Vaginitis","Vaginal Atrophy","Genitourinary Syndrome of Menopause","Lichen Sclerosus of Vulva","Lichen Planus of Vulva","Lichen Simplex of Vulva (Disorder)","RECRUITING","2026-02-19",{"date":35,"type":36},"2026-02-20","ACTUAL",{"date":38,"type":36},"2023-10-30",{"date":40,"type":20},"2028-12",{"name":42,"class":43},"Stratpharma AG","INDUSTRY",14,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100619566","phase-4-assist-vla-assessment-of-symptom-specific-improvement-in-diagnosed-vaginal-atrophy-following-laser-therapy-100619566","NCT07346287","ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy","Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy (ASSIST-VLA)","ASSIST-VLA","Inclusion Criteria:\n\n* Diagnosed vaginal atrophy\n* Access to smartphone and tablet, laptop or computer\n* Access to a valid email address\n* Previously completed laser therapy session schedule\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Patient unable to apply topical device\n* Allergy or intolerance to ingredients or excipients of the formulation of studied products\n* Systemic hormonal or steroidal therapy started less than 30 days before baseline ( = not yet on a stable regimen)",{"count":54,"type":20},10,[56],"PHASE4","Vaginal atrophy patients receiving vaginal laser therapy will be treated with daily 7-0940® following a laser session to evaluate the safety and efficacy of the product as an adjunct treatment. Clinical outcomes will be assessed using validated investigator- and patient-reported measures, with safety and symptom progression monitored throughout the study.",[27,26,59],"Genitourinary Syndrome of Menopause (GSM)","2026-01-15",{"date":62,"type":36},"2026-01-16",{"date":64,"type":36},"2025-08-13",{"date":66,"type":20},"2026-04",{"name":42,"class":43},1]